{"ticker": {"uuid": "9de26ac3-ef1e-4317-b207-b26df479107e", "symbol": "BTAI", "name": "BioXcel Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "BioXcel Therapeutics (BTAI) Registration Filing Summary", "summary": "This summary details BioXcel Therapeutics' (BTAI) registration filing, outlining its business model focused on neuroscience and immuno-oncology using AI platforms. It highlights the company's lead asset, BXCL501 (IGALMI), approved for acute agitation, and discusses recent financi", "url": "https://quartr.com/events/bioxcel-therapeutics-inc-btai-registration-filing_onNWKPzm", "source_name": "Quartr", "published_at": "2026-07-14T02:47:14", "published_display": "14 Jul 2026 02:47", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (BTAI) Q2 2024 earnings summary", "summary": "BioXcel Therapeutics (BTAI) reported a Q2 2024 net revenue of $1.1M, a 141% increase year-over-year, driven by IGALMI. The company significantly reduced operating expenses and narrowed its net loss to $8.3M, but faces substantial doubt about its ability to continue as a going con", "url": "https://quartr.com/events/bioxcel-therapeutics-inc-btai-q2-2024_onNWy6bC", "source_name": "Quartr", "published_at": "2026-07-13T14:10:52", "published_display": "13 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (BTAI) Q4 2025 earnings summary", "summary": "BioXcel Therapeutics (BTAI) reported its Q4 2025 earnings, highlighting a submitted sNDA for IGALMI's at-home use with potential approval by year-end 2026 and continued expansion of BXCL501 clinical programs. Financially, the company saw a significant drop in IGALMI net revenue y", "url": "https://quartr.com/events/bioxcel-therapeutics-inc-btai-q4-2025_onNWKYT6", "source_name": "Quartr", "published_at": "2026-07-13T11:10:53", "published_display": "13 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel (NASDAQ: BTAI) eases liquidity covenant and defers $9M loan payment", "summary": "BioXcel Therapeutics has amended its loan agreement with Oaktree to gain flexibility on debt payments and liquidity covenants, including deferring a $9 million principal payment. The agreement capitalizes accrued interest through June 30, 2026, defers a June 30 principal payment ", "url": "https://www.stocktitan.net/sec-filings/BTAI/8-k-bio-xcel-therapeutics-inc-reports-material-event-d658a6afe065.html", "source_name": "Stock Titan", "published_at": "2026-07-06T09:40:56", "published_display": "06 Jul 2026 09:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTAI - BioXcel Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of BioXcel Therapeutics Inc (BTAI), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider and institutional ownership, and short inte", "url": "https://finviz.com/stock?t=BTAI&ty=oc", "source_name": "Finviz", "published_at": "2026-07-05T11:40:56", "published_display": "05 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTAI - BioXcel Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for BioXcel Therapeutics Inc (BTAI), including real-time stock performance data, financial metrics, and company statistics. It details key financial ratios, insider and institutional ownership, and volume and volatility indi", "url": "https://finviz.com/stock?t=BTAI&ty=lf&p=m", "source_name": "Finviz", "published_at": "2026-07-05T02:39:52", "published_display": "05 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioXcel Therapeutics, Inc. \u2013 NASDAQ:BTAI", "summary": "This article provides access to the \"Price to sales forward\" financial metric for BioXcel Therapeutics, Inc. (NASDAQ: BTAI) on the TradingView platform. It indicates that the market is currently closed with no trades. The content is primarily a navigation and copyright informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-BTAI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T00:09:47", "published_display": "02 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell Microcap Index", "summary": "BioXcel Therapeutics, Inc. (BTAI) has been added to the Russell Microcap Index. The biopharmaceutical company utilizes artificial intelligence to develop medicines in neuroscience and immuno-oncology, with lead candidates BXCL501 for agitation and BXCL701 for aggressive cancers. ", "url": "https://www.marketscreener.com/news/bioxcel-therapeutics-inc-nasdaqcm-btai-added-to-russell-microcap-index-ce7f5fdeda80f124", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:42:04", "published_display": "29 Jun 2026 05:42", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioXcel Therapeutics, Inc. \u2013 NASDAQ:BTAI", "summary": "This article provides financial data for BioXcel Therapeutics, Inc. (NASDAQ: BTAI), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section from a financial data platform like TradingView, indicating specific financial metrics for t", "url": "https://www.tradingview.com/symbols/NASDAQ-BTAI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:40:49", "published_display": "28 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of BioXcel Therapeutics, Inc. \u2013 NASDAQ:BTAI", "summary": "This article provides financial information for BioXcel Therapeutics, Inc. (NASDAQ: BTAI), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of the data capture, with no trades reported. The information is presented ", "url": "https://www.tradingview.com/symbols/NASDAQ-BTAI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:37", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yocca Frank", "summary": "This document is a statement of changes in beneficial ownership of securities for Frank Yocca, an officer at BioXcel Therapeutics. It is filed as a Form 4, indicating a transaction or change in his holdings of the company's stock.", "url": "https://www.moomoo.com/news/notice/307548755/bioxcel-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-27T03:10:37", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc. Actuals & Estimates (FWB:BX20)", "summary": "This article provides an overview of BioXcel Therapeutics, Inc. (FWB:BX20) financial data and analyst estimates, including income statement, balance sheet, and cash flow. It details stock forecasts, historical price movements, recent earnings, revenue figures, and employee count.", "url": "https://www.tradingview.com/symbols/FWB-BX20/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-26T17:39:43", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc. Actuals & Estimates (NASDAQ:BTAI)", "summary": "This article provides an overview of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) stock performance, actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report dates. The article also co", "url": "https://www.tradingview.com/symbols/NASDAQ-BTAI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:43", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain", "summary": "BioXcel Therapeutics, Inc. (BTAI) CFO Richard I. Steinhart exercised derivative awards on June 15, 2026, acquiring 35 shares of Common Stock from Restricted Stock Units (RSUs). This transaction increased his direct Common Stock holdings to 26,335 shares, while 212 RSUs remain. Th", "url": "https://www.stocktitan.net/sec-filings/BTAI/form-4-bio-xcel-therapeutics-inc-insider-trading-activity-ac54fe5e5ebd.html", "source_name": "Stock Titan", "published_at": "2026-06-18T16:39:30", "published_display": "18 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares", "summary": "BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, converted 35 Restricted Stock Units (RSUs) into common shares on June 15, 2026. This transaction increased his direct holdings to 26,210 common shares, with 212 RSUs remaining from an original grant of 562 units on Marc", "url": "https://www.stocktitan.net/sec-filings/BTAI/form-4-bio-xcel-therapeutics-inc-insider-trading-activity-7a199d998de4.html", "source_name": "Stock Titan", "published_at": "2026-06-18T00:09:03", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock", "summary": "Javier Rodriguez, an officer at BioXcel Therapeutics (NASDAQ: BTAI), converted 35 Restricted Stock Units (RSUs) into 35 shares of Common Stock on June 15, 2026, at a price of $0.00 per share. This was a vesting-related derivative exercise, not an open-market purchase. Following t", "url": "https://www.stocktitan.net/sec-filings/BTAI/form-4-bio-xcel-therapeutics-inc-insider-trading-activity-8f20a3a1aac8.html", "source_name": "Stock Titan", "published_at": "2026-06-18T00:09:02", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of BioXcel Therapeutics Inc (BTAI), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over recent quarters, and recent shareholder activity. The information h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-btai/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:03", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of BioXcel Therapeutics Inc (BTAI) stock's dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and lists several upcoming merger-related stock splits scheduled for February 6, 20", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-btai/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:03", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel (BTAI) CEO exercises 219 RSUs and reports major indirect stakes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdGMzalBBc1Jpa2kwNkg5amtRbXY5YXNVaU9KT3NGLWRnSUNPU0RSNGpvNzVTT2w3c0FNcHNjVDgtOW43cGhUb2hsbjFkQXR2SDVhVVp4RHM0MWIwUzRRTXZ1TTJyT2pINS1XRFBldlkzTTQtb016ai0zWmZQMlh1dXktRHg1WERoQW85ZWNxcDh1d0dQN0lTUzl6NzExa0dBMjQ0SUNDMm96UmIwM0R6SGRaVmtOdE1VX3dB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment?", "summary": "BioXcel Therapeutics (BTAI) saw its stock increase by 5% after announcing positive Phase 2 results for its opioid withdrawal treatment, BXCL501. The drug significantly reduced withdrawal symptoms by over 30% and showed a favorable safety profile, performing comparably or better t", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-btai-stock-surge-in-pre-market-today/cZdQs29RI3E", "source_name": "Stocktwits", "published_at": "2026-06-06T11:39:47", "published_display": "06 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What makes BioXcel Therapeutics (BTAI) a new buy stock", "summary": "The article provides insights into why BioXcel Therapeutics (BTAI) has been designated as a \"new buy\" stock. It highlights key factors and recent developments that are attracting investor interest in the company. The analysis likely covers the company's financial health, product ", "url": "https://www.msn.com/en-us/money/topstocks/what-makes-bioxcel-therapeutics-btai-a-new-buy-stock/ar-AA24EXLX", "source_name": "MSN", "published_at": "2026-06-03T12:39:03", "published_display": "03 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Shareholder Action Reminder", "summary": "Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and is reminding investors of the upcoming September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The investigation follows a sign", "url": "https://www.newsfilecorp.com/release/177142/BioXcel-Shareholder-Action-Reminder?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-02T11:39:05", "published_display": "02 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Presents New Data from SERENITY", "summary": "BioXcel Therapeutics announced new positive data from its Phase 3 SERENITY At-Home trial for BXCL501, showing its effectiveness in reducing agitation across all baseline severity levels in patients with bipolar disorders or schizophrenia. The company presented these findings at t", "url": "https://www.globenewswire.com/news-release/2026/05/28/3302675/0/en/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-with-bipolar-disorders-or-schizophrenia-at-2026-ascp-annual-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T09:10:19", "published_display": "29 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia", "summary": "BioXcel Therapeutics announced positive new data from its Phase 3 SERENITY At-Home trial for BXCL501 (sublingual dexmedetomidine), designed to treat agitation associated with bipolar disorders or schizophrenia in an at-home setting. The analyses showed that BXCL501 significantly ", "url": "https://www.marketscreener.com/news/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-ce7f5ddadb8cf723", "source_name": "www.marketscreener.com", "published_at": "2026-05-28T12:09:08", "published_display": "28 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 85, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI)", "summary": "This article provides recent news and financial updates for BioXcel Therapeutics Inc. (NASDAQ: BTAI). Key updates include the company's Q1 loss and missed revenue estimates as reported by Zacks, as well as BioXcel's own business update and Q1 2026 financial results. The stock 'BT", "url": "https://www.chartmill.com/stock/quote/BTAI/news", "source_name": "ChartMill", "published_at": "2026-05-28T08:09:25", "published_display": "28 May 2026 08:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics | 424B5: Prospectus", "summary": "This document is a prospectus, specifically a 424B5 filing from BioXcel Therapeutics. These filings are used to register securities with the SEC and provide essential information to potential investors about the offering. The content would detail the terms of the offering, compan", "url": "https://www.moomoo.com/news/notice/306640247/bioxcel-therapeutics-424b5-prospectus", "source_name": "Moomoo", "published_at": "2026-05-28T01:09:08", "published_display": "28 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com", "summary": "Vimal Mehta, CEO of BioXcel Therapeutics (NASDAQ:BTAI), sold 19,419 shares of company stock worth $21,108 on May 20, 2026, stemming from the vesting of restricted stock units. This transaction was executed under a Rule 10b5-1 trading plan to cover tax obligations. Despite the sal", "url": "https://ng.investing.com/news/insider-trading-news/bioxcel-therapeutics-ceo-mehta-sells-21108-in-company-stock-93CH-2527341", "source_name": "Investing.com Nigeria", "published_at": "2026-05-24T06:09:13", "published_display": "24 May 2026 06:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment", "summary": "BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, recently engaged in equity compensation activities. He exercised 17,500 Restricted Stock Units (RSUs) on May 4, 2026, and subsequently sold 6,845 common shares on May 20, 2026, at a weighted average price of $1.085 per ", "url": "https://www.stocktitan.net/sec-filings/BTAI/form-4-bio-xcel-therapeutics-inc-insider-trading-activity-0772c0b7fe8f.html", "source_name": "Stock Titan", "published_at": "2026-05-23T22:39:37", "published_display": "23 May 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com", "summary": "BioXcel Therapeutics' Chief Legal Officer, Javier Rodriguez, recently sold $7,111 worth of company stock to cover taxes related to restricted stock unit vesting. The transactions were executed under a Rule 10b5-1 trading plan. The stock is currently trading near its 52-week low, ", "url": "https://ng.investing.com/news/insider-trading-news/bioxcel-therapeutics-chief-legal-officer-sells-7111-in-stock-93CH-2527343", "source_name": "Investing.com Nigeria", "published_at": "2026-05-23T10:40:39", "published_display": "23 May 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics chief legal officer sells $7,111 in stock", "summary": "Javier Rodriguez, Chief Legal Officer at BioXcel Therapeutics, Inc. (NASDAQ:BTAI), recently sold $7,111 worth of company stock to cover taxes associated with restricted stock unit vesting. These transactions occurred as BTAI trades near its 52-week low. The company is also workin", "url": "https://m.investing.com/news/insider-trading-news/bioxcel-therapeutics-chief-legal-officer-sells-7111-in-stock-93CH-4707823?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-23T05:09:52", "published_display": "23 May 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOaXhYVVpDbHZQMVg4VjlxaTZoWjdaZkxNbmczaWU1R0RoX0cyUElTQ29jV0ZGaG1uRkFVMHJTQVFCVjNmQVNSdjhEMHFIMTczWE1mNUpCemFIMTZBUHhIeGV2Q1B0ZVZVd01WMVJRbmNnRFJraHQxcE5kQXRDRUdtX282T1N5dm5vdXNmNFA1Y2pnYnRLN2tCZVY1TGhQT3ZaYnRtSGhzdjl4ZEt4UFk4WlZHS2N6NU9iWHlMMVNabTRqVHlUU0dpeg?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel CFO Richard Steinhart sells $7,426 of stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPMmF0Qm5DS2J1MWoxeTdzQWtnOW45U2VCOGNNSmJuQThxQUczT2loaktmQ29VQU5tSmFDSklOWmZTeHNlTTRQbmpJUnhfTEFTeXgxcEpXYjRUUkhXM0hrRXBlRTZfc29pamk5cnR6TGMtOURqYUF4ZHVWem5ramVzV3dkM1dKXzNSOXV6b0dDSVdHbzlRTFozYjNoOWZrME5CV05zQ0laQ290RExWckY4T1Z5NlM?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxQSkhvQk8yaEMxYXpoMjJfZFVmaHc0TmhBMkxSZlBGMVFKd1VEUlgtb3ppcl8zejBvQ2w3MUdEekdNV0xfbWlPQzJMeUV1TUJoNjBOZ1NleGs4ZTFrTXhTOGQtSUlocUl4bmozUE9DT1c5b3lZSDVmV2t3VDBXZDdLaW92Sko1eFhMc015UGFFaU5tRl9FQzdNcmVFdlEwZWhVNVFDdnU0TjJDYjRraGFVSUdHSDVOZXd2ekY4ejhaZmJKOUNaODN6XzFiT0dGejZHTVd5R2M5b3lfZHZSM0piNUdiTDBKUk5lbWc3ZHB4U0lVY2VHNHVmYUFR?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel at-home agitation drug gets Nov. 14, 2026 FDA action date", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPY3Q5QkxfY2J3d1U2Tk1nVEJwRWp0ZXFwUXNWSEo5aVFTN1JBeFZZUDAwNEJ1R0lmbGxkbTh6bXNZY0tfNlpsWlI0b1BzQmNwTUlWejU2cUdJbk1oMlRtVVhBRzJOUG9MdUt5Si1rd1U3NjJwRmhmTnVOeWRxU0JEaWlaYkhSSXhPMWlPNjRwZnc1bmtkUmxra3JndXc2YzVvNTRsTllpZkZWckVDTjRBLS1rbzdGbndSTzdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVWVONXlPV2FPXzh1M25hVzZlakdoNEtpRFVRY2hQMno2a1VkRzFIbmVhMWxaTHU3WUZMV3JOM2Q1cjNhRGpQd2Vqb2xoR2ptZEo3UGU4R3plbXVYenFWQ2lqcnNjUWxOejhhMVVMaEg2YkoxSm9hT0x2SzBTX1pwallVOVh0N1RUbjgyd0ZfWFBWUVJXRU5TNkVNNGNWMFhFelNTckNYSjhGUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPLUhxVlZiZXhGZm44Si13WEt4MEpJR2dqdkEzeGlBSERnR2hkaGdtTUxDQ2RVRkpFcUJaT0JUcFRZNVdBZXlqRW1SUXUxelBJQnd2X1Jhb0Iwa2FKQThTYXgtMGludi1UUFdpY2tuVFB1cEcxSDctRWYwYU1faFNVa3dnZVdrNzE5ZVE4Tmh2WEdOOWRFb25WVFgzSXhHRDBFV3h6S2xB?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel\u00a0Therapeutics\u00a0Announces\u00a0Virtual\u00a0Event to Discuss\u00a0Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI\u00ae\u00a0in\u00a0the At-Home Setting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/bioxcel-therapeutics-announces-virtual-event-110000978.html", "source_name": "GlobeNewswire", "published_at": "2026-04-17T11:00:00+00:00", "published_display": "17 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOc0FpZkNPRzl6RWdmcy1CZ2lidUhvQy1NMndaUFFKbWR1OU1MUERGalpQZkl1RnV3d05wUFZ6SGJsZ0k5Yzc4NDNvTk5jUFVCSFAwSGh2ckRhSHUyTWZFdWN5M3lsZWtVRzhrVmt2eTlQajVqWEp0UjJVMlhyRjVLSGRPWUZJUFg3MnlGalRwM3FKU2gzQkxmY2ppZEJVYUo2?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZ2xxdFpDVFBOQmNJSTZncXpBUmowYk1iQXlNaFl0TnZyNjR4bG5mU3JHTjA4MFlTTTZQdXFrQlBuS0Z5cjNGTW1iZXplZ0dNS2ltd21ZV0Q3RWJUMGNtN0xmT3drZ3hOU0R2X2VvZ1FNMEVtV0tNXzJEUVdzZnc2b0lCby1VYXpjeXJMd3c3ZmFnX0hMcS1pRjA3TXgxVWVIQzdwMXVtNFU?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel seeks first at-home FDA-approved agitation treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPZkNldUs5NHdQQ2xrb2t3ODZmbzh5WGVfUVpzX192MGdBYWQ4X1JFbi1fUmNNNGNQQnFoVnRRbmlNRFQ2NExIRm1KXy1FdkM3dHdWLUVIZmRSOEpfYnRKRWx2azJzNXgweVRmOXM4VVhJWW4tREJvTVFTV0lZOF9vZzV5b2xUdFh3d21mQ2Ria1pRNzE3YktsUzhJVXp5Rko1RnREQ0tFblN0RTdFVUJWeTNUNlIwbmhSUmZaSnAtUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNLXNtQ2xxcWctRUE1MVBoeG5pV2dKVFZqaWU4Ym94NjZYeUM2SFZyalVVcjZJZ1FxeXM2T1p2NHBCd1lOejVGRC1sOHhwRGo0eXJuZWJMZDRWZ0drOUpGNTBCVmd0eUllLTNSMjJZTkxpelRybHdnc0V2RmkyWFN3Vm5oVU16c0I2azYzaE9hQjBnd01hM0VCbUVFRG9VVDlGc0p4WGFoNTNKXzJYT1E?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics raises $8M in stock offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPLXBYMXYtckh0YUxNczEwSFBTdmxkVzRvRnZ5QjFiUWtmT2JkRk1MV3pIdndmVjNhQnNFNEp1YjV1c20yd05NNl9fYUJjNGRsNlkzOE5fczFvQjQ4X1hpaXBMaTVESzFmMHd5SmhYa2pxMkZVUlluZThjTE1EQ1F3Q290eXpBZVBoTXBtZ3pYQQ?oc=5", "source_name": "Hartford Business Journal", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxORFJwVlpZeEFCTFpsSkNRcWxNa2pFUGZuSHdodnNNR3N1MGQ0c05JRzlxV3I1dXNVbDR2TmNYM01DWjdpenhRWG01NDRNOUQ1MWZDd2d1cmdrZ0RjX0tYakgybC1fcmdPQ1BzSFExVGltVUZUWE9SSHVCblJYMDJEbVZfX1htdXFkaVZoRTlGdw?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI-driven drugmaker BioXcel raises $8M, extends investor warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOa1JJcHpOQ2p6T1VtZFpVb2FGX3Z4UFJqYnIzakppZ1ZXa0F0cEc2cV9saWdYQzZ3Z0RMcmc0c1RTNWtfNW9udzRkbWxUQzF1R1R1NUxHV0ZRWWIyUmxaWDFva3hLX0RFblQwOGlrZDdHZmVJZk9XMWtLWEh0a2tUTjNZNFdIVHhENU1scHcwMVh6SmtmN2RpMTl4bFoyWXl5VjlsV3dIWXdmaG1zSlQzZ1dGbGd5bHNCdEthSg?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Seeks Market Expansion amid Financial Struggles", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOb0I0Z1ZpSnJVTGhldFZrYVY4b0RnaXhBT19PTFVuUFdZQWhMc2hfOW5OeGZOWkdCUEZrMmZwbktHeGM1WEtFSGZyZUZQdGp5V1JrakJGcndTTGV2Q0tDSFIybkhYTTIzcFFKTDVzUHdjdEVrNHRZeWc2b3dtZXp3X2xuVVdMRThGdFE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI\u00ae in the At-Home Setting", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSEZCZkI4ZGZpYjVkVUphRXQwSzI0TUlXMWtBWFBoUHlyMzZGakNweUp0M0RRcjRNcTlHZUdtcnozbEFaUHJYdU12Q3FOLWVUcDd4bTJ0TXk1M0lxWEw4Y1l4V0dXcUNBZ09haGxIRll2RzdST2ZBX3hUSEFYUWpqRHppb0lTSUtLZTRBY0NJbllncnZQVEJHcngzUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel to seek approval for at-home use of agitation drug after upbeat study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNTDBXaEdKWXBkclZjY1FXRTlqdmtMb25sUnotMU40QXBjbVJucjU1R3RjbDVqM0kzYkVad3JUX0dKYXlMRHFoeFE4N1RPZ1pBdnhhSFBjZjNGWGh2cWZBVU50T2dITnAxMWI2MnJkcm5mS05pa0tZRXNXRTdicVdVS2c1OGJ6NXE4LXlkNEtUblJkTlVKdHRIVTYtM0hEMFBoeDBQYUxpYzRHRmNXeU56WmM1NGYyc3RveG1xaUpwMXg5MlF2ck9oYm1aYVV6VWc1em1uOTNn?oc=5", "source_name": "Reuters", "published_at": "2025-08-27T07:00:00+00:00", "published_display": "27 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNcTdiT3BlTjQtcjJZajJGRUt3R2sxT0pqNDBPdjhMdnp1VUU5LVhXeUkyd2I2aTd2cWozaUFDNWRqczBobFltSDdpZHVpTjFuWXZKdEQ5RnBFM0ZVVERuVE9kYnVBNk9rY1cwSUJreXU1WTVVQ2VNeXY5d1pocXFWZXNlUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] BioXcel Therapeutics, Inc. Reports Material Event | BTAI 8-K Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOZ21YODhNbGJPUXlHUnJpVFczY3RmZFFSU3p1VkRYUUJFNFlXQk9udl9WczE4V0h4aFBaY0RMcEY1WHNkZXhMcE12UlpwdXdSMnV1cFhpWUtXX240ZDhiSzRWbldnQ1psdUhjT1lfVFRYc0FxQlgwSWgtOUNyS283aFZnNFFqRXIweHg1dXM4b3ZDM2EtbjUyNm1FQjRQNVFRMmxaSGxpNUJjaGM2cnhKYm9iREM?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-15T07:00:00+00:00", "published_display": "15 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioxcel Therapeutics (BTAI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5HWGRJaE11QWx4ZEl0d3VmNjRqMG9EZHM2UXZKN3NmS2xuTGdBdHliRzg5a2M5aVFNYVBsUXpqbzBtS0ltVEx3bGt4NHJ6MkJEbTFN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:31:39+00:00", "published_display": "25 Apr 2025 02:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top execs at New Haven-based BioXcel face compensation reductions amid company\u2019s financial struggles", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSm9hU3U2Uk54b3UwbUZxZUdzT1RFbzZiYjVpeklQSHNOam1ZR2Yyb1MwQ3ZXNTlIQlNLeWl1dU1lbnJVbkFtTlpiLVNheFZfWUFhQXVHejlOazR2aDB5bVU0aHQ3ZENkYnl4bkRReDIxZ3d5YmRqdDE5R3JIMFF1U0pORFhDc2pGZWtZQVZjblpBazdPU2JvbFdxZXRxRVhLVVFGdG9XOTYyQ2x6OUc5Z3Yya3I5RjhDbldneU9ncGJhQWlHeXc?oc=5", "source_name": "Hartford Business Journal", "published_at": "2025-01-08T08:00:00+00:00", "published_display": "08 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BioXcel Therapeutics (BTAI) Registration Filing Summary", "summary": "This summary details BioXcel Therapeutics' (BTAI) registration filing, outlining its business model focused on neuroscience and immuno-oncology using AI platforms. It highlights the company's lead asset, BXCL501 (IGALMI), approved for acute agitation, and discusses recent financi", "url": "https://quartr.com/events/bioxcel-therapeutics-inc-btai-registration-filing_onNWKPzm", "source_name": "Quartr", "published_at": "2026-07-14T02:47:14", "published_display": "14 Jul 2026 02:47", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (BTAI) Q2 2024 earnings summary", "summary": "BioXcel Therapeutics (BTAI) reported a Q2 2024 net revenue of $1.1M, a 141% increase year-over-year, driven by IGALMI. The company significantly reduced operating expenses and narrowed its net loss to $8.3M, but faces substantial doubt about its ability to continue as a going con", "url": "https://quartr.com/events/bioxcel-therapeutics-inc-btai-q2-2024_onNWy6bC", "source_name": "Quartr", "published_at": "2026-07-13T14:10:52", "published_display": "13 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (BTAI) Q4 2025 earnings summary", "summary": "BioXcel Therapeutics (BTAI) reported its Q4 2025 earnings, highlighting a submitted sNDA for IGALMI's at-home use with potential approval by year-end 2026 and continued expansion of BXCL501 clinical programs. Financially, the company saw a significant drop in IGALMI net revenue y", "url": "https://quartr.com/events/bioxcel-therapeutics-inc-btai-q4-2025_onNWKYT6", "source_name": "Quartr", "published_at": "2026-07-13T11:10:53", "published_display": "13 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel (NASDAQ: BTAI) eases liquidity covenant and defers $9M loan payment", "summary": "BioXcel Therapeutics has amended its loan agreement with Oaktree to gain flexibility on debt payments and liquidity covenants, including deferring a $9 million principal payment. The agreement capitalizes accrued interest through June 30, 2026, defers a June 30 principal payment ", "url": "https://www.stocktitan.net/sec-filings/BTAI/8-k-bio-xcel-therapeutics-inc-reports-material-event-d658a6afe065.html", "source_name": "Stock Titan", "published_at": "2026-07-06T09:40:56", "published_display": "06 Jul 2026 09:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTAI - BioXcel Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of BioXcel Therapeutics Inc (BTAI), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider and institutional ownership, and short inte", "url": "https://finviz.com/stock?t=BTAI&ty=oc", "source_name": "Finviz", "published_at": "2026-07-05T11:40:56", "published_display": "05 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTAI - BioXcel Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for BioXcel Therapeutics Inc (BTAI), including real-time stock performance data, financial metrics, and company statistics. It details key financial ratios, insider and institutional ownership, and volume and volatility indi", "url": "https://finviz.com/stock?t=BTAI&ty=lf&p=m", "source_name": "Finviz", "published_at": "2026-07-05T02:39:52", "published_display": "05 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioXcel Therapeutics, Inc. \u2013 NASDAQ:BTAI", "summary": "This article provides access to the \"Price to sales forward\" financial metric for BioXcel Therapeutics, Inc. (NASDAQ: BTAI) on the TradingView platform. It indicates that the market is currently closed with no trades. The content is primarily a navigation and copyright informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-BTAI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T00:09:47", "published_display": "02 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell Microcap Index", "summary": "BioXcel Therapeutics, Inc. (BTAI) has been added to the Russell Microcap Index. The biopharmaceutical company utilizes artificial intelligence to develop medicines in neuroscience and immuno-oncology, with lead candidates BXCL501 for agitation and BXCL701 for aggressive cancers. ", "url": "https://www.marketscreener.com/news/bioxcel-therapeutics-inc-nasdaqcm-btai-added-to-russell-microcap-index-ce7f5fdeda80f124", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:42:04", "published_display": "29 Jun 2026 05:42", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BioXcel Therapeutics, Inc. \u2013 NASDAQ:BTAI", "summary": "This article provides financial data for BioXcel Therapeutics, Inc. (NASDAQ: BTAI), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section from a financial data platform like TradingView, indicating specific financial metrics for t", "url": "https://www.tradingview.com/symbols/NASDAQ-BTAI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T08:40:49", "published_display": "28 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of BioXcel Therapeutics, Inc. \u2013 NASDAQ:BTAI", "summary": "This article provides financial information for BioXcel Therapeutics, Inc. (NASDAQ: BTAI), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of the data capture, with no trades reported. The information is presented ", "url": "https://www.tradingview.com/symbols/NASDAQ-BTAI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:37", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yocca Frank", "summary": "This document is a statement of changes in beneficial ownership of securities for Frank Yocca, an officer at BioXcel Therapeutics. It is filed as a Form 4, indicating a transaction or change in his holdings of the company's stock.", "url": "https://www.moomoo.com/news/notice/307548755/bioxcel-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-27T03:10:37", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc. Actuals & Estimates (FWB:BX20)", "summary": "This article provides an overview of BioXcel Therapeutics, Inc. (FWB:BX20) financial data and analyst estimates, including income statement, balance sheet, and cash flow. It details stock forecasts, historical price movements, recent earnings, revenue figures, and employee count.", "url": "https://www.tradingview.com/symbols/FWB-BX20/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-26T17:39:43", "published_display": "26 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc. Actuals & Estimates (NASDAQ:BTAI)", "summary": "This article provides an overview of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) stock performance, actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report dates. The article also co", "url": "https://www.tradingview.com/symbols/NASDAQ-BTAI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:43", "published_display": "26 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain", "summary": "BioXcel Therapeutics, Inc. (BTAI) CFO Richard I. Steinhart exercised derivative awards on June 15, 2026, acquiring 35 shares of Common Stock from Restricted Stock Units (RSUs). This transaction increased his direct Common Stock holdings to 26,335 shares, while 212 RSUs remain. Th", "url": "https://www.stocktitan.net/sec-filings/BTAI/form-4-bio-xcel-therapeutics-inc-insider-trading-activity-ac54fe5e5ebd.html", "source_name": "Stock Titan", "published_at": "2026-06-18T16:39:30", "published_display": "18 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares", "summary": "BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, converted 35 Restricted Stock Units (RSUs) into common shares on June 15, 2026. This transaction increased his direct holdings to 26,210 common shares, with 212 RSUs remaining from an original grant of 562 units on Marc", "url": "https://www.stocktitan.net/sec-filings/BTAI/form-4-bio-xcel-therapeutics-inc-insider-trading-activity-7a199d998de4.html", "source_name": "Stock Titan", "published_at": "2026-06-18T00:09:03", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock", "summary": "Javier Rodriguez, an officer at BioXcel Therapeutics (NASDAQ: BTAI), converted 35 Restricted Stock Units (RSUs) into 35 shares of Common Stock on June 15, 2026, at a price of $0.00 per share. This was a vesting-related derivative exercise, not an open-market purchase. Following t", "url": "https://www.stocktitan.net/sec-filings/BTAI/form-4-bio-xcel-therapeutics-inc-insider-trading-activity-8f20a3a1aac8.html", "source_name": "Stock Titan", "published_at": "2026-06-18T00:09:02", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of BioXcel Therapeutics Inc (BTAI), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over recent quarters, and recent shareholder activity. The information h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-btai/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:03", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of BioXcel Therapeutics Inc (BTAI) stock's dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and lists several upcoming merger-related stock splits scheduled for February 6, 20", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-btai/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:03", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel (BTAI) CEO exercises 219 RSUs and reports major indirect stakes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdGMzalBBc1Jpa2kwNkg5amtRbXY5YXNVaU9KT3NGLWRnSUNPU0RSNGpvNzVTT2w3c0FNcHNjVDgtOW43cGhUb2hsbjFkQXR2SDVhVVp4RHM0MWIwUzRRTXZ1TTJyT2pINS1XRFBldlkzTTQtb016ai0zWmZQMlh1dXktRHg1WERoQW85ZWNxcDh1d0dQN0lTUzl6NzExa0dBMjQ0SUNDMm96UmIwM0R6SGRaVmtOdE1VX3dB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment?", "summary": "BioXcel Therapeutics (BTAI) saw its stock increase by 5% after announcing positive Phase 2 results for its opioid withdrawal treatment, BXCL501. The drug significantly reduced withdrawal symptoms by over 30% and showed a favorable safety profile, performing comparably or better t", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-btai-stock-surge-in-pre-market-today/cZdQs29RI3E", "source_name": "Stocktwits", "published_at": "2026-06-06T11:39:47", "published_display": "06 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What makes BioXcel Therapeutics (BTAI) a new buy stock", "summary": "The article provides insights into why BioXcel Therapeutics (BTAI) has been designated as a \"new buy\" stock. It highlights key factors and recent developments that are attracting investor interest in the company. The analysis likely covers the company's financial health, product ", "url": "https://www.msn.com/en-us/money/topstocks/what-makes-bioxcel-therapeutics-btai-a-new-buy-stock/ar-AA24EXLX", "source_name": "MSN", "published_at": "2026-06-03T12:39:03", "published_display": "03 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Shareholder Action Reminder", "summary": "Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and is reminding investors of the upcoming September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The investigation follows a sign", "url": "https://www.newsfilecorp.com/release/177142/BioXcel-Shareholder-Action-Reminder?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-02T11:39:05", "published_display": "02 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Presents New Data from SERENITY", "summary": "BioXcel Therapeutics announced new positive data from its Phase 3 SERENITY At-Home trial for BXCL501, showing its effectiveness in reducing agitation across all baseline severity levels in patients with bipolar disorders or schizophrenia. The company presented these findings at t", "url": "https://www.globenewswire.com/news-release/2026/05/28/3302675/0/en/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-with-bipolar-disorders-or-schizophrenia-at-2026-ascp-annual-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T09:10:19", "published_display": "29 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia", "summary": "BioXcel Therapeutics announced positive new data from its Phase 3 SERENITY At-Home trial for BXCL501 (sublingual dexmedetomidine), designed to treat agitation associated with bipolar disorders or schizophrenia in an at-home setting. The analyses showed that BXCL501 significantly ", "url": "https://www.marketscreener.com/news/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-ce7f5ddadb8cf723", "source_name": "www.marketscreener.com", "published_at": "2026-05-28T12:09:08", "published_display": "28 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 85, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI)", "summary": "This article provides recent news and financial updates for BioXcel Therapeutics Inc. (NASDAQ: BTAI). Key updates include the company's Q1 loss and missed revenue estimates as reported by Zacks, as well as BioXcel's own business update and Q1 2026 financial results. The stock 'BT", "url": "https://www.chartmill.com/stock/quote/BTAI/news", "source_name": "ChartMill", "published_at": "2026-05-28T08:09:25", "published_display": "28 May 2026 08:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics | 424B5: Prospectus", "summary": "This document is a prospectus, specifically a 424B5 filing from BioXcel Therapeutics. These filings are used to register securities with the SEC and provide essential information to potential investors about the offering. The content would detail the terms of the offering, compan", "url": "https://www.moomoo.com/news/notice/306640247/bioxcel-therapeutics-424b5-prospectus", "source_name": "Moomoo", "published_at": "2026-05-28T01:09:08", "published_display": "28 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com", "summary": "Vimal Mehta, CEO of BioXcel Therapeutics (NASDAQ:BTAI), sold 19,419 shares of company stock worth $21,108 on May 20, 2026, stemming from the vesting of restricted stock units. This transaction was executed under a Rule 10b5-1 trading plan to cover tax obligations. Despite the sal", "url": "https://ng.investing.com/news/insider-trading-news/bioxcel-therapeutics-ceo-mehta-sells-21108-in-company-stock-93CH-2527341", "source_name": "Investing.com Nigeria", "published_at": "2026-05-24T06:09:13", "published_display": "24 May 2026 06:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment", "summary": "BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, recently engaged in equity compensation activities. He exercised 17,500 Restricted Stock Units (RSUs) on May 4, 2026, and subsequently sold 6,845 common shares on May 20, 2026, at a weighted average price of $1.085 per ", "url": "https://www.stocktitan.net/sec-filings/BTAI/form-4-bio-xcel-therapeutics-inc-insider-trading-activity-0772c0b7fe8f.html", "source_name": "Stock Titan", "published_at": "2026-05-23T22:39:37", "published_display": "23 May 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com", "summary": "BioXcel Therapeutics' Chief Legal Officer, Javier Rodriguez, recently sold $7,111 worth of company stock to cover taxes related to restricted stock unit vesting. The transactions were executed under a Rule 10b5-1 trading plan. The stock is currently trading near its 52-week low, ", "url": "https://ng.investing.com/news/insider-trading-news/bioxcel-therapeutics-chief-legal-officer-sells-7111-in-stock-93CH-2527343", "source_name": "Investing.com Nigeria", "published_at": "2026-05-23T10:40:39", "published_display": "23 May 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics chief legal officer sells $7,111 in stock", "summary": "Javier Rodriguez, Chief Legal Officer at BioXcel Therapeutics, Inc. (NASDAQ:BTAI), recently sold $7,111 worth of company stock to cover taxes associated with restricted stock unit vesting. These transactions occurred as BTAI trades near its 52-week low. The company is also workin", "url": "https://m.investing.com/news/insider-trading-news/bioxcel-therapeutics-chief-legal-officer-sells-7111-in-stock-93CH-4707823?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-23T05:09:52", "published_display": "23 May 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOaXhYVVpDbHZQMVg4VjlxaTZoWjdaZkxNbmczaWU1R0RoX0cyUElTQ29jV0ZGaG1uRkFVMHJTQVFCVjNmQVNSdjhEMHFIMTczWE1mNUpCemFIMTZBUHhIeGV2Q1B0ZVZVd01WMVJRbmNnRFJraHQxcE5kQXRDRUdtX282T1N5dm5vdXNmNFA1Y2pnYnRLN2tCZVY1TGhQT3ZaYnRtSGhzdjl4ZEt4UFk4WlZHS2N6NU9iWHlMMVNabTRqVHlUU0dpeg?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel CFO Richard Steinhart sells $7,426 of stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPMmF0Qm5DS2J1MWoxeTdzQWtnOW45U2VCOGNNSmJuQThxQUczT2loaktmQ29VQU5tSmFDSklOWmZTeHNlTTRQbmpJUnhfTEFTeXgxcEpXYjRUUkhXM0hrRXBlRTZfc29pamk5cnR6TGMtOURqYUF4ZHVWem5ramVzV3dkM1dKXzNSOXV6b0dDSVdHbzlRTFozYjNoOWZrME5CV05zQ0laQ290RExWckY4T1Z5NlM?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxQSkhvQk8yaEMxYXpoMjJfZFVmaHc0TmhBMkxSZlBGMVFKd1VEUlgtb3ppcl8zejBvQ2w3MUdEekdNV0xfbWlPQzJMeUV1TUJoNjBOZ1NleGs4ZTFrTXhTOGQtSUlocUl4bmozUE9DT1c5b3lZSDVmV2t3VDBXZDdLaW92Sko1eFhMc015UGFFaU5tRl9FQzdNcmVFdlEwZWhVNVFDdnU0TjJDYjRraGFVSUdHSDVOZXd2ekY4ejhaZmJKOUNaODN6XzFiT0dGejZHTVd5R2M5b3lfZHZSM0piNUdiTDBKUk5lbWc3ZHB4U0lVY2VHNHVmYUFR?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel at-home agitation drug gets Nov. 14, 2026 FDA action date", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPY3Q5QkxfY2J3d1U2Tk1nVEJwRWp0ZXFwUXNWSEo5aVFTN1JBeFZZUDAwNEJ1R0lmbGxkbTh6bXNZY0tfNlpsWlI0b1BzQmNwTUlWejU2cUdJbk1oMlRtVVhBRzJOUG9MdUt5Si1rd1U3NjJwRmhmTnVOeWRxU0JEaWlaYkhSSXhPMWlPNjRwZnc1bmtkUmxra3JndXc2YzVvNTRsTllpZkZWckVDTjRBLS1rbzdGbndSTzdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVWVONXlPV2FPXzh1M25hVzZlakdoNEtpRFVRY2hQMno2a1VkRzFIbmVhMWxaTHU3WUZMV3JOM2Q1cjNhRGpQd2Vqb2xoR2ptZEo3UGU4R3plbXVYenFWQ2lqcnNjUWxOejhhMVVMaEg2YkoxSm9hT0x2SzBTX1pwallVOVh0N1RUbjgyd0ZfWFBWUVJXRU5TNkVNNGNWMFhFelNTckNYSjhGUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPLUhxVlZiZXhGZm44Si13WEt4MEpJR2dqdkEzeGlBSERnR2hkaGdtTUxDQ2RVRkpFcUJaT0JUcFRZNVdBZXlqRW1SUXUxelBJQnd2X1Jhb0Iwa2FKQThTYXgtMGludi1UUFdpY2tuVFB1cEcxSDctRWYwYU1faFNVa3dnZVdrNzE5ZVE4Tmh2WEdOOWRFb25WVFgzSXhHRDBFV3h6S2xB?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel\u00a0Therapeutics\u00a0Announces\u00a0Virtual\u00a0Event to Discuss\u00a0Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI\u00ae\u00a0in\u00a0the At-Home Setting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/bioxcel-therapeutics-announces-virtual-event-110000978.html", "source_name": "GlobeNewswire", "published_at": "2026-04-17T11:00:00+00:00", "published_display": "17 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOc0FpZkNPRzl6RWdmcy1CZ2lidUhvQy1NMndaUFFKbWR1OU1MUERGalpQZkl1RnV3d05wUFZ6SGJsZ0k5Yzc4NDNvTk5jUFVCSFAwSGh2ckRhSHUyTWZFdWN5M3lsZWtVRzhrVmt2eTlQajVqWEp0UjJVMlhyRjVLSGRPWUZJUFg3MnlGalRwM3FKU2gzQkxmY2ppZEJVYUo2?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZ2xxdFpDVFBOQmNJSTZncXpBUmowYk1iQXlNaFl0TnZyNjR4bG5mU3JHTjA4MFlTTTZQdXFrQlBuS0Z5cjNGTW1iZXplZ0dNS2ltd21ZV0Q3RWJUMGNtN0xmT3drZ3hOU0R2X2VvZ1FNMEVtV0tNXzJEUVdzZnc2b0lCby1VYXpjeXJMd3c3ZmFnX0hMcS1pRjA3TXgxVWVIQzdwMXVtNFU?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel seeks first at-home FDA-approved agitation treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPZkNldUs5NHdQQ2xrb2t3ODZmbzh5WGVfUVpzX192MGdBYWQ4X1JFbi1fUmNNNGNQQnFoVnRRbmlNRFQ2NExIRm1KXy1FdkM3dHdWLUVIZmRSOEpfYnRKRWx2azJzNXgweVRmOXM4VVhJWW4tREJvTVFTV0lZOF9vZzV5b2xUdFh3d21mQ2Ria1pRNzE3YktsUzhJVXp5Rko1RnREQ0tFblN0RTdFVUJWeTNUNlIwbmhSUmZaSnAtUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNLXNtQ2xxcWctRUE1MVBoeG5pV2dKVFZqaWU4Ym94NjZYeUM2SFZyalVVcjZJZ1FxeXM2T1p2NHBCd1lOejVGRC1sOHhwRGo0eXJuZWJMZDRWZ0drOUpGNTBCVmd0eUllLTNSMjJZTkxpelRybHdnc0V2RmkyWFN3Vm5oVU16c0I2azYzaE9hQjBnd01hM0VCbUVFRG9VVDlGc0p4WGFoNTNKXzJYT1E?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics raises $8M in stock offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPLXBYMXYtckh0YUxNczEwSFBTdmxkVzRvRnZ5QjFiUWtmT2JkRk1MV3pIdndmVjNhQnNFNEp1YjV1c20yd05NNl9fYUJjNGRsNlkzOE5fczFvQjQ4X1hpaXBMaTVESzFmMHd5SmhYa2pxMkZVUlluZThjTE1EQ1F3Q290eXpBZVBoTXBtZ3pYQQ?oc=5", "source_name": "Hartford Business Journal", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxORFJwVlpZeEFCTFpsSkNRcWxNa2pFUGZuSHdodnNNR3N1MGQ0c05JRzlxV3I1dXNVbDR2TmNYM01DWjdpenhRWG01NDRNOUQ1MWZDd2d1cmdrZ0RjX0tYakgybC1fcmdPQ1BzSFExVGltVUZUWE9SSHVCblJYMDJEbVZfX1htdXFkaVZoRTlGdw?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI-driven drugmaker BioXcel raises $8M, extends investor warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOa1JJcHpOQ2p6T1VtZFpVb2FGX3Z4UFJqYnIzakppZ1ZXa0F0cEc2cV9saWdYQzZ3Z0RMcmc0c1RTNWtfNW9udzRkbWxUQzF1R1R1NUxHV0ZRWWIyUmxaWDFva3hLX0RFblQwOGlrZDdHZmVJZk9XMWtLWEh0a2tUTjNZNFdIVHhENU1scHcwMVh6SmtmN2RpMTl4bFoyWXl5VjlsV3dIWXdmaG1zSlQzZ1dGbGd5bHNCdEthSg?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Seeks Market Expansion amid Financial Struggles", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOb0I0Z1ZpSnJVTGhldFZrYVY4b0RnaXhBT19PTFVuUFdZQWhMc2hfOW5OeGZOWkdCUEZrMmZwbktHeGM1WEtFSGZyZUZQdGp5V1JrakJGcndTTGV2Q0tDSFIybkhYTTIzcFFKTDVzUHdjdEVrNHRZeWc2b3dtZXp3X2xuVVdMRThGdFE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI\u00ae in the At-Home Setting", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSEZCZkI4ZGZpYjVkVUphRXQwSzI0TUlXMWtBWFBoUHlyMzZGakNweUp0M0RRcjRNcTlHZUdtcnozbEFaUHJYdU12Q3FOLWVUcDd4bTJ0TXk1M0lxWEw4Y1l4V0dXcUNBZ09haGxIRll2RzdST2ZBX3hUSEFYUWpqRHppb0lTSUtLZTRBY0NJbllncnZQVEJHcngzUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel to seek approval for at-home use of agitation drug after upbeat study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNTDBXaEdKWXBkclZjY1FXRTlqdmtMb25sUnotMU40QXBjbVJucjU1R3RjbDVqM0kzYkVad3JUX0dKYXlMRHFoeFE4N1RPZ1pBdnhhSFBjZjNGWGh2cWZBVU50T2dITnAxMWI2MnJkcm5mS05pa0tZRXNXRTdicVdVS2c1OGJ6NXE4LXlkNEtUblJkTlVKdHRIVTYtM0hEMFBoeDBQYUxpYzRHRmNXeU56WmM1NGYyc3RveG1xaUpwMXg5MlF2ck9oYm1aYVV6VWc1em1uOTNn?oc=5", "source_name": "Reuters", "published_at": "2025-08-27T07:00:00+00:00", "published_display": "27 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNcTdiT3BlTjQtcjJZajJGRUt3R2sxT0pqNDBPdjhMdnp1VUU5LVhXeUkyd2I2aTd2cWozaUFDNWRqczBobFltSDdpZHVpTjFuWXZKdEQ5RnBFM0ZVVERuVE9kYnVBNk9rY1cwSUJreXU1WTVVQ2VNeXY5d1pocXFWZXNlUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] BioXcel Therapeutics, Inc. Reports Material Event | BTAI 8-K Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOZ21YODhNbGJPUXlHUnJpVFczY3RmZFFSU3p1VkRYUUJFNFlXQk9udl9WczE4V0h4aFBaY0RMcEY1WHNkZXhMcE12UlpwdXdSMnV1cFhpWUtXX240ZDhiSzRWbldnQ1psdUhjT1lfVFRYc0FxQlgwSWgtOUNyS283aFZnNFFqRXIweHg1dXM4b3ZDM2EtbjUyNm1FQjRQNVFRMmxaSGxpNUJjaGM2cnhKYm9iREM?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-15T07:00:00+00:00", "published_display": "15 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioxcel Therapeutics (BTAI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5HWGRJaE11QWx4ZEl0d3VmNjRqMG9EZHM2UXZKN3NmS2xuTGdBdHliRzg5a2M5aVFNYVBsUXpqbzBtS0ltVEx3bGt4NHJ6MkJEbTFN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:31:39+00:00", "published_display": "25 Apr 2025 02:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top execs at New Haven-based BioXcel face compensation reductions amid company\u2019s financial struggles", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSm9hU3U2Uk54b3UwbUZxZUdzT1RFbzZiYjVpeklQSHNOam1ZR2Yyb1MwQ3ZXNTlIQlNLeWl1dU1lbnJVbkFtTlpiLVNheFZfWUFhQXVHejlOazR2aDB5bVU0aHQ3ZENkYnl4bkRReDIxZ3d5YmRqdDE5R3JIMFF1U0pORFhDc2pGZWtZQVZjblpBazdPU2JvbFdxZXRxRVhLVVFGdG9XOTYyQ2x6OUc5Z3Yya3I5RjhDbldneU9ncGJhQWlHeXc?oc=5", "source_name": "Hartford Business Journal", "published_at": "2025-01-08T08:00:00+00:00", "published_display": "08 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 82, "total_relevant": 51, "sentiment_summary": {"positive": 10, "negative": 10, "neutral": 31, "score": 51, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 10}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.45, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 0.82, "latest_week": "2026-07-10", "one_week_move": -40.8, "four_week_move": -28.3, "twelve_week_move": -28.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.028806, "market_dynamics_buy_signal": false, "relative_strength": -64.886803, "fair_value_gap": -96.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 35.5907, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-40.8% over one week, -28.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 5}, {"label": "Quartr", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "Finviz", "count": 2}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 10}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-40.8% over one week, -28.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "BioXcel Therapeutics (BTAI) Registration Filing Summary"}], "updated_at": "2026-07-16T08:52:18.350141+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}